These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32870366)

  • 1. Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Vale CA; Egan PC; Ingham R; Farmakiotis D; Reagan JL
    Ann Hematol; 2021 Jan; 100(1):79-84. PubMed ID: 32870366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
    Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
    Bradley AM; Deal AM; Buie LW; van Deventer H
    Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
    Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Rattarittamrong E; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e915-e921. PubMed ID: 35792033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
    Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
    Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Kolla BC; Halim NAA; Cao Q; Sachs Z; Warlick E; Weisdorf D; Ho AYL; Chuan WG; Lao Z; He F
    Br J Haematol; 2021 Jul; 194(1):140-144. PubMed ID: 33843048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Ochs MA; Perissinotti AJ; Marini BL; Burke PW; Bixby DL; Pettit KM; Benitez LL
    Leuk Res; 2021 Mar; 102():106517. PubMed ID: 33561633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
    Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia.
    Azevedo MC; Velloso ED; Buccheri V; Chamone DA; Dorlhiac-Llacer PE
    Braz J Med Biol Res; 2015 Feb; 48(2):178-85. PubMed ID: 25517921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
    Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
    Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
    Sperr WR; Herndlhofer S; Gleixner K; Girschikofsky M; Weltermann A; Machherndl-Spandl S; Sliwa T; Poehnl R; Buxhofer-Ausch V; Strecker K; Hoermann G; Knoebl P; Jaeger U; Geissler K; Kundi M; Valent P
    Am J Hematol; 2017 Oct; 92(10):E567-E574. PubMed ID: 28699225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Miyamoto T; Nagafuji K; Fujisaki T; Uchida N; Matsue K; Henzan H; Ogawa R; Takase K; Aoki T; Hidaka M; Teshima T; Taniguchi S; Akashi K; Harada M;
    Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
    Sljivic I; Fulford A; Ho J; Lazo-Langner A; Xenocostas A; Deotare U
    Eur J Haematol; 2023 Dec; 111(6):888-894. PubMed ID: 37640495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
    Shepshelovich D; Edel Y; Goldvaser H; Dujovny T; Wolach O; Raanani P
    Br J Clin Pharmacol; 2015 Apr; 79(4):685-91. PubMed ID: 25303309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
    Ciftciler R; Demiroglu H; Buyukasık Y; Okay M; Aksu S; Sayınalp N; Malkan UY; Haznedaroglu IC; Ozcebe O; Goker H
    Transfus Apher Sci; 2018 Dec; 57(6):752-755. PubMed ID: 30249531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
    Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
    Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.
    Kimura S; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Yamasaki R; Ashizawa M; Machishima T; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
    Hematology; 2014 Mar; 19(2):107-12. PubMed ID: 23683842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.